Tarsus Pharmaceuticals, Inc.
TARS
$46.47
$2.906.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 948.62% | 801.96% | 566.99% | 53.22% | -32.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 948.62% | 801.96% | 566.99% | 53.22% | -32.42% |
| Cost of Revenue | 36.91% | 32.19% | 29.79% | 30.95% | -9.25% |
| Gross Profit | 682.78% | 492.47% | 284.20% | 136.82% | -24.43% |
| SG&A Expenses | 118.32% | 163.03% | 196.30% | 178.67% | 141.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.99% | 110.88% | 121.49% | 106.89% | 81.42% |
| Operating Income | 15.78% | -23.58% | -63.33% | -128.77% | -128.28% |
| Income Before Tax | 14.97% | -24.87% | -64.99% | -127.04% | -118.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.97% | -24.87% | -65.00% | -127.06% | -118.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.97% | -24.87% | -65.00% | -127.06% | -118.86% |
| EBIT | 15.78% | -23.58% | -63.33% | -128.77% | -128.28% |
| EBITDA | 16.12% | -23.26% | -62.99% | -128.54% | -128.06% |
| EPS Basic | 33.11% | 0.54% | -31.80% | -93.66% | -80.68% |
| Normalized Basic EPS | 35.06% | 4.33% | -27.30% | -90.95% | -80.03% |
| EPS Diluted | 33.18% | 0.66% | -31.63% | -93.01% | -80.37% |
| Normalized Diluted EPS | 35.06% | 4.33% | -27.30% | -90.95% | -80.03% |
| Average Basic Shares Outstanding | 29.23% | 29.36% | 26.90% | 19.38% | 18.00% |
| Average Diluted Shares Outstanding | 29.23% | 29.36% | 26.90% | 19.38% | 18.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
